GlassScriptPhysician profile
James T Miller
NPI 1063783942
$1,185.21
in general payments reported to CMS, 2019-2025
17 companies · $40.49 in 2025
The $40.49 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $717 · 2023: $183 · 2024: $244 · 2025: $40.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $307.41 | 2021-2024 | Airsupra |
| Lilly USA, LLC | $265.65 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $122.11 | 2021 | |
| Sanofi-Aventis U.S. LLC | $64.93 | 2021 | |
| Abbott Laboratories | $62.72 | 2021-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $60.61 | 2021 | |
| Glaxosmithkline, LLC. | $44.74 | 2021 | |
| Exact Sciences Corporation | $35.98 | 2023-2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $35.64 | 2021 | |
| Novo Nordisk INC | $35.15 | 2021 | |
| Ironwood Pharmaceuticals, INC | $35.10 | 2021 | |
| Currax Pharmaceuticals LLC | $24.47 | 2021 | |
| Melinta Therapeutics, LLC | $23.40 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.75 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $16.77 | 2024 | Omnipod |
| Esperion Therapeutics, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.